Psoriasis is an immune-mediated disease, with the interleukin (IL)-23/IL-17 axis currently
considered its main pathogenic pathway. Tyrosine kinase 2 (TYK2) is responsible for …

Psoriasis is a common inflammatory skin disease involving interactions between
keratinocytes and immune cells that significantly affects the quality of life. It is characterized …

Janus kinase (JAK) inhibitors are novel treatment approaches for psoriasis. However, there
is no direct comparison of JAK inhibitors in plaque psoriasis. In order to compare the efficacy …

Increasing understanding of cytokines as major drivers of immune‐mediated diseases has
revolutionized targeted treatments for these conditions. As the pathogenesis of autoimmune …

A member of the Janus kinase (JAK) family, Tyrosine Kinase 2 (TYK2), is crucial in
mediating various cytokine-signaling pathways such as interleukin-23 (IL23), interleukin-12 …

ABSTRACT Introduction Tyrosine kinase 2 (TYK2) is a member of the JAK family class of
kinases that is responsible for mediating the immune response to IL-12, IL-23, and IFNα. The …

Abstract Tyrosine kinase 2 (TYK2), a key part of the Janus kinase-signal transducer and
activator of transcription (JAK-STAT) pathway, plays an integral role in the differentiation and …

Introduction Up to now, a total of eight Janus kinase (JAK) inhibitors have been approved for
the treatment of autoimmune and myeloproliferative disease. The JAK family belongs to the …

Tyrosine kinase 2 (TYK2) mediates the interleukin-23 (IL-23), IL-12, and type I interferon
(IFN)-driven signal responses that are critical in autoimmune diseases. Here, a series of …

Introduction Hidradenitis suppurativa (HS) is a chronic, debilitating inflammatory skin
disorder characterized by painful nodules, abscesses, fistulae, and scarring with a …